|
1
|
Liu Y, Zhang W, Hu T, Ni J, Xu B and Huang
W: A doxorubicin-induced murine model of dilated cardiomyopathy in
vivo. J Vis Exp: May 16, 2020 (Epub ahead of print). doi:
10.3791/61158.
|
|
2
|
Rocca C, Scavello F, Colombo B, Gasparri
AM, Dallatomasina A, Granieri MC, Amelio D, Pasqua T, Cerra MC,
Tota B, et al: Physiological levels of chromogranin A prevent
doxorubicin-induced cardiotoxicity without impairing its anticancer
activity. FASEB J. 33:7734–7747. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang S, Ding L, Ji H, Xu Z, Liu Q and
Zheng Y: The role of p38 MAPK in the development of diabetic
cardiomyopathy. Int J Mol Sci. 17(1037)2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kankeu C, Clarke K, Passante E and Huber
HJ: Doxorubicin-induced chronic dilated cardiomyopathy-the
apoptosis hypothesis revisited. J Mol Med (Berl). 95:239–248.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cheng X, Liu D, Xing R, Song H, Tian X,
Yan C and Han Y: Orosomucoid 1 attenuates doxorubicin-induced
oxidative stress and apoptosis in cardiomyocytes via Nrf2
signaling. Biomed Res Int. 2020(5923572)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Song T, Yao Y, Wang T, Huang H and Xia H:
Tanshinone IIA ameliorates apoptosis of myocardiocytes by
up-regulation of miR-133 and suppression of caspase-9. Eur J
Pharmacol. 815:343–350. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yao Y, Xu X, Zhang G, Zhang Y, Qian W and
Rui T: Role of HMGB1 in doxorubicin-induced myocardial apoptosis
and its regulation pathway. Basic Res Cardiol.
107(267)2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zeng C, Duan F, Hu J, Luo B, Huang B, Lou
X, Sun X, Li H, Zhang X, Yin S and Tan H: NLRP3
inflammasome-mediated pyroptosis contributes to the pathogenesis of
non-ischemic dilated cardiomyopathy. Redox Biol.
34(101523)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li J, Wang PY, Long NA, Zhuang J, Springer
DA, Zou J, Lin Y, Bleck CKE, Park JH, Kang JG and Hwang PM: p53
prevents doxorubicin cardiotoxicity independently of its
prototypical tumor suppressor activities. Proc Natl Acad Sci USA.
116:19626–19634. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mizutani H, Tada-Oikawa S, Hiraku Y,
Kojima M and Kawanishi S: Mechanism of apoptosis induced by
doxorubicin through the generation of hydrogen peroxide. Life Sci.
76:1439–1453. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Reeve JL, Szegezdi E, Logue SE, Ní
Chonghaile T, O'Brien T, Ritter T and Samali A: Distinct mechanisms
of cardiomyocyte apoptosis induced by doxorubicin and hypoxia
converge on mitochondria and are inhibited by Bcl-xL. J Cell Mol
Med. 11:509–520. 2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rogers NM, Zhang ZJ, Wang JJ, Thomson AW
and Isenberg JS: CD47 regulates renal tubular epithelial cell
self-renewal and proliferation following renal ischemia
reperfusion. Kidney Int. 90:334–347. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ghimire K, Li Y, Chiba T, Julovi SM, Li J,
Ross MA, Straub AC, O'Connell PJ, Rüegg C, Pagano PJ, et al: CD47
promotes age-associated deterioration in angiogenesis, blood flow
and glucose homeostasis. Cells. 9(1695)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kaur S, Bronson SM, Pal-Nath D, Miller TW,
Soto-Pantoja DR and Roberts DD: Functions of thrombospondin-1 in
the tumor microenvironment. Int J Mol Sci. 22(4570)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rath GM, Schneider C, Dedieu S, Rothhut B,
Soula-Rothhut M, Ghoneim C, Sid B, Morjani H, El Btaouri H and
Martiny L: The C-terminal CD47/IAP-binding domain of
thrombospondin-1 prevents camptothecin- and doxorubicin-induced
apoptosis in human thyroid carcinoma cells. Biochim Biophys Acta.
1763:1125–1134. 2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Feliz-Mosquea YR, Christensen AA, Wilson
AS, Westwood B, Varagic J, Meléndez GC, Schwartz AL, Chen QR,
Mathews Griner L, Guha R, et al: Combination of anthracyclines and
anti-CD47 therapy inhibit invasive breast cancer growth while
preventing cardiac toxicity by regulation of autophagy. Breast
Cancer Res Treat. 172:69–82. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lo J, Lau EY, So FT, Lu P, Chan VS, Cheung
VC, Ching RH, Cheng BY, Ma MK, Ng IO and Lee TK: Anti-CD47 antibody
suppresses tumour growth and augments the effect of chemotherapy
treatment in hepatocellular carcinoma. Liver Int. 36:737–745.
2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tong B and Wang M: CD47 is a novel potent
immunotherapy target in human malignancies: Current studies and
future promises. Future Oncol. 14:2179–2188. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Veillette A and Chen J: SIRPα-CD47 immune
checkpoint blockade in anticancer therapy. Trends Immunol.
39:173–184. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chen M, Wang Y, Wang H, Sun L, Fu Y and
Yang YG: Elimination of donor CD47 protects against vascularized
allograft rejection in mice. Xenotransplantation.
26(e12459)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Rogers NM, Sharifi-Sanjani M, Yao M,
Ghimire K, Bienes-Martinez R, Mutchler SM, Knupp HE, Baust J,
Novelli EM, Ross M, et al: TSP1-CD47 signaling is upregulated in
clinical pulmonary hypertension and contributes to pulmonary
arterial vasculopathy and dysfunction. Cardiovasc Res. 113:15–29.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sharifi-Sanjani M, Shoushtari AH, Quiroz
M, Baust J, Sestito SF, Mosher M, Ross M, McTiernan CF, St Croix
CM, Bilonick RA, et al: Cardiac CD47 drives left ventricular heart
failure through Ca2+-CaMKII-regulated induction of
HDAC3. J Am Heart Assoc. 3(e000670)2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Li Y, Zhao K, Zong P, Fu H, Zheng Y, Bao
D, Yin Y, Chen Q, Lu L, Dai Y, et al: CD47 deficiency protects
cardiomyocytes against hypoxia/reoxygenation injury by rescuing
autophagic clearance. Mol Med Rep. 19:5453–5463. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang HB and Yang J, Ding JW, Chen LH, Li
S, Liu XW, Yang CJ, Fan ZX and Yang J: RNAi-mediated
down-regulation of CD47 protects against
ischemia/reperfusion-induced myocardial damage via activation of
eNOS in a rat model. Cell Physiol Biochem. 40:1163–1174.
2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Li Y, Chen X, Li P, Xiao Q, Hou D and Kong
X: CD47 antibody suppresses isoproterenol-induced cardiac
hypertrophy through activation of autophagy. Am J Transl Res.
12:5908–5923. 2020.PubMed/NCBI
|
|
26
|
Li M, Sala V, De Santis MC, Cimino J,
Cappello P, Pianca N, Di Bona A, Margaria JP, Martini M, Lazzarini
E, et al: Phosphoinositide 3-kinase gamma inhibition protects from
anthracycline cardiotoxicity and reduces tumor growth. Circulation.
138:696–711. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hu C, Zhang X, Wei W, Zhang N, Wu H, Ma Z,
Li L, Deng W and Tang Q: Matrine attenuates oxidative stress and
cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via
maintaining AMPKα/UCP2 pathway. Acta Pharm Sin B. 9:690–701.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Rui T, Cepinskas G, Feng Q and Kvietys PR:
Delayed preconditioning in cardiac myocytes with respect to
development of a proinflammatory phenotype: Role of SOD and NOS.
Cardiovasc Res. 59:901–911. 2003.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kojima Y, Volkmer JP, McKenna K, Civelek
M, Lusis AJ, Miller CL, Direnzo D, Nanda V, Ye J, Connolly AJ, et
al: CD47-blocking antibodies restore phagocytosis and prevent
atherosclerosis. Nature. 536:86–90. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tal MC, Torrez Dulgeroff LB, Myers L, Cham
LB, Mayer-Barber KD, Bohrer AC, Castro E, Yiu YY, Lopez Angel C,
Pham E, et al: Upregulation of CD47 is a host checkpoint response
to pathogen recognition. mBio. 11:e01293–20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Deuse T, Hu X, Agbor-Enoh S, Jang MK,
Alawi M, Saygi C, Gravina A, Tediashvili G, Nguyen VQ, Liu Y, et
al: The SIRPα-CD47 immune checkpoint in NK cells. J Exp Med.
218(e20200839)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Novelli EM, Little-Ihrig L, Knupp HE,
Rogers NM, Yao M, Baust JJ, Meijles D, St Croix CM, Ross MA, Pagano
PJ, et al: Vascular TSP1-CD47 signaling promotes sickle
cell-associated arterial vasculopathy and pulmonary hypertension in
mice. Am J Physiol Lung Cell Mol Physiol. 316:L1150–L1164.
2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Jarr KU, Nakamoto R, Doan BH, Kojima Y,
Weissman IL, Advani RH, Iagaru A and Leeper NJ: Effect of CD47
blockade on vascular inflammation. N Engl J Med. 384:382–383.
2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Xiao D and Zhang L: Upregulation of Bax
and Bcl-2 following prenatal cocaine exposure induces apoptosis in
fetal rat brain. Int J Med Sci. 5:295–302. 2008.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Cao Y, Ruan Y, Shen T, Huang X, Li M, Yu
W, Zhu Y, Man Y, Wang S and Li J: Astragalus polysaccharide
suppresses doxorubicin-induced cardiotoxicity by regulating the
PI3k/Akt and p38MAPK pathways. Oxid Med Cell Longev.
2014(674219)2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Xuan T, Wang D, Lv J, Pan Z, Fang J, Xiang
Y, Cheng H, Wang X and Guo X: Downregulation of Cypher induces
apoptosis in cardiomyocytes via Akt/p38 MAPK signaling pathway. Int
J Med Sci. 17:2328–2337. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zuo G, Ren X, Qian X, Ye P, Luo J, Gao X,
Zhang J and Chen S: Inhibition of JNK and p38 MAPK-mediated
inflammation and apoptosis by ivabradine improves cardiac function
in streptozotocin-induced diabetic cardiomyopathy. J Cell Physiol.
234:1925–1936. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gerlach BD, Marinello M, Heinz J, Rymut N,
Sansbury BE, Riley CO, Sadhu S, Hosseini Z, Kojima Y, Tang DD, et
al: Resolvin D1 promotes the targeting and clearance of necroptotic
cells. Cell Death Differ. 27:525–539. 2020.PubMed/NCBI View Article : Google Scholar
|
